The B4GALT1 Knockout KYSE-30 Polyclonal Cells are a polyclonal population of KYSE-30 human esophageal squamous epithelial cells with CRISPR/Cas9-mediated disruption of the B4GALT1 gene. This polyclonal knockout model provides a heterogeneous loss-of-function system for studying beta-1,4-galactosyltransferase I in a cancer-relevant cellular context.
KYSE-30 cells are derived from a well-differentiated human esophageal squamous cell carcinoma and retain epithelial morphology. They serve as a widely used model for esophageal squamous cell carcinoma (ESCC), a malignancy with limited therapeutic options and a high metastatic potential. The cells express characteristic epithelial markers and exhibit adhesive and invasive properties dependent on cell surface glycoprotein glycosylation.
B4GALT1 encodes beta-1,4-galactosyltransferase I, a Golgi-resident enzyme that transfers galactose from UDP-galactose to terminal N-acetylglucosamine residues, forming lactosamine linkages on nascent glycoproteins. Its activity is essential for the elongation of N-glycans, O-glycans, and glycosaminoglycans, and is regulated upstream by EGF receptor signaling, TGF-??, and the SP1 transcription factor, as well as post-transcriptionally by the miR-200 family. Downstream, B4GALT1-mediated glycosylation modifies key cell adhesion molecules, including integrins (ITGB1, ITGA3) and E-cadherin, influencing their stability, ligand binding, and signaling. The enzyme interacts with alpha-lactalbumin to form the lactose synthase complex in mammary tissue, but in ESCC it primarily functions in the modification of integrin heterodimers and extracellular matrix (ECM) proteins such as laminin-binding glycans.
Disruption of B4GALT1 in KYSE-30 polyclonal knockout cells leads to aberrant hypoglycosylation of surface glycoproteins, thereby impairing integrin-mediated adhesion to ECM components and attenuating downstream signaling pathways that drive migration and invasion. Since B4GALT1 is implicated in the epithelial-mesenchymal transition (EMT) and metastatic dissemination of esophageal carcinoma, this knockout model offers a powerful tool to dissect the role of glycosylation in cancer progression. The polyclonal nature of the knockout population captures the heterogeneity of CRISPR edits, enabling the study of bulk glycosylation defects without clonal selection biases.
Typical applications include functional studies of glycosylation in ESCC biology, such as glycomic profiling by lectin blotting, cell adhesion and migration assays, and EMT marker analysis. The cells are suitable for investigating B4GALT1 as a potential therapeutic target, evaluating how loss of glycosylation affects drug sensitivity, and conducting RNA-seq to map transcriptional changes in glycosylation networks. Flow cytometry for cell surface glycans and immunofluorescence for Golgi markers can assess glycocalyx integrity. Researchers are encouraged to contact Ascent Research for technical support and customization options to further exploit this model in their specific experimental designs.
